SFDA keeps two lists, and you are on one
The MHRA is a stringent authority in Saudi Arabia, and that buys you a materially faster clock — 280 working days instead of 405. It does not buy you the fast routes. Verification and abridged registration name three reference agencies, and the MHRA is not among them.
What does an MHRA authorisation actually buy?
A faster clock. Not a shorter route.
SFDA's Regulatory Framework for Drugs Approval, version 6.4, defines stringent regulatory authorities for human products as "USFDA, EMA, MHRA (UK), Swissmedic, Health Canada, TGA (Australia) and PMDA (Japan)". That definition drives the timetable: a new drug or biologic already registered with a stringent authority is assessed in 280 working days; one that is not takes 405. On priority review the figure is 168.
But the two genuinely short routes are governed by a different document, and it names a different set. Under the verification and abridged pathways guidance, "FDA, USDA and EMA are considered as reference agencies". The MHRA does not appear in it. The United Kingdom appears only in that guidance's list of eligible manufacturing countries.
- Verification — 30 working daysClosed on MHRA alone
Requires approval by both the FDA and the EMA, both assessment reports, and submission within two years of the reference approval
- Abridged — 60 working daysClosed on MHRA alone
Requires approval by one of FDA, USDA or EMA, with that agency's assessment report and the same two-year window
- Regular, new drug or biologic — 280 working daysOpen
The stringent-authority tier. This is the one an MHRA authorisation unlocks
- Priority review — 168 working daysOpen
For products registered with a stringent authority
- Regular generic — 155 working daysOpen
Bioequivalence data, not prior approval, is what carries it
And one contradiction we will not smooth over. A third current SFDA document, the data requirements for human drug submissions updated in August 2025, still speaks of a "reference member state in EU, USA, Canada, Switzerland, Australia and Japan". No United Kingdom. That is a pre-Brexit formulation surviving in a live text. Our reading is that the framework controls, because it governs pathway eligibility and is the later statement on the point — but your regulatory manager may read the dossier guidance and reach the opposite conclusion, and both of you will be quoting a current SFDA document correctly.
An agent, unless you hold an investment licence
The registration rules put it plainly: "The foreign companies that do not own a commercial investment license from the Ministry of Investment must appoint an agent or more for each pharmaceutical or herbal product that is intended to be marketed in the kingdom." Per product, not per company.
That phrasing repays attention. The obligation is escapable — an investment licence removes it — and it attaches product by product, which means a portfolio can sit with more than one agent. Both facts are commercial levers, and neither is available to a device manufacturer in this market, where the representative model is rigid.
Separately, a company with a registered factory in the Kingdom needs a scientific office headed by a full-time Saudi pharmacist holding a practice licence, carrying responsibility for product information, marketing ethics, registration tracking, post-marketing safety, and a pharmacovigilance section with its own designated pharmacist. No pharmaceutical establishment may operate without an SFDA licence at all, and that licence runs five renewable years.
The clocks, and a fee schedule from 2011
| Pathway | Working days | Application fee, SAR |
|---|---|---|
| Verification | 30 | — |
| Abridged | 60 | — |
| Regular — generic | 155 | 40,000 |
| Priority — new drug or biologic, stringent-registered | 168 | 95,000 |
| Regular — new drug or biologic, stringent-registered | 280 | 95,000 |
| Regular — new drug or biologic, not stringent-registered | 405 | 95,000 |
| Licence renewal — new drug or biologic | — | 30,000 |
| Licence renewal — generic | — | 10,000 |
| New concentration · new pack type | — | 24,000 · 24,000 |
| Pre-registration price estimation | — | 20,000 |
| GMP certificate | — | 500 |
Timelines from the Regulatory Framework version 6.4, in force 1 October 2023; each figure is the total across technical validation, business validation, evaluation and inspection, pricing and licensing, and the clock pauses while your clarifications are outstanding. Pricing is a twenty working day stage inside every one of them. Fees are from an administrative decision of 2011 that SFDA still hosts — we found nothing newer and we re-confirm before quoting. Separately the statutory registration fee is SAR 1,000 per concentration, form or pack, on registration and on renewal. A marketing authorisation runs five renewable years.
Saudi Arabia has stopped asking for a certificate of pharmaceutical product.
In SFDA's own words, "CPP / free-sales submission is optional and no longer required for new Marketing Authorization applications (MAA) within all regulatory pathways". Egypt, Türkiye, Nigeria and the UAE all still require one — Nigeria wants it legalised at its High Commission. If you are sequencing the Gulf, this is one document less, and it is worth knowing before somebody quotes you for obtaining it.
Your British price is an input to your Saudi price
The United Kingdom is one of sixteen benchmark countries in SFDA's pricing rules, alongside Australia, Austria, Belgium, Canada, France, Germany, Hungary, Italy, Japan, the Netherlands, Poland, Portugal, South Korea, Spain and Sweden.
There is no single formula. The committee weighs added therapeutic value, the prices of locally registered alternatives, pharmacoeconomic evidence, ex-factory and wholesale prices in the manufacturing and origin countries, and the export price in every country where the product is marketed. What is mechanical is what happens afterwards.
From the pricing rules in force since January 2021. A single re-pricing event may not exceed 30%, and no reduction may follow within two years of the last one — though the committee may re-evaluate sooner for high-cost products or where health outcomes must be demonstrated. At renewal, products priced under SAR 30 are exempt from re-pricing.
This is the part of a Saudi launch that a UK company most often models wrongly. The registration timetable is published and knowable; the price erosion is published too, and it is the thing that decides whether year four looks like your business case.
Your site is registered separately, and SFDA may inspect it
Manufacturer registration is a distinct regime from product registration, with its own chapter in the rules. The file wants a GMP certificate from the regulatory authority in the country of origin with proof of inspection, the list of products you make with their registration and marketing dates, the countries where each is registered with certificate copies, a site master file, the production lines to be registered, and inspection fees. Renewal is filed at least six months before expiry.
An MHRA or EU GMP certificate satisfies the origin-country requirement on its face. What it does not do is remove SFDA's own right of inspection: the rules state that "The SFDA inspects the manufacturer to ensure the implementation of Good Manufacturing Practice" and that it may assign a technical team to do so. There is no mutual recognition agreement and no published list of GMP authorities whose certificate substitutes for an inspection.
One favourable development. SFDA was admitted to the international inspection cooperation scheme in May 2023, the first Arab authority to join. That does not create an entitlement, but it puts SFDA inside the same inspection framework as the MHRA — which is a better starting position for a conversation about inspection reliance than existed three years ago.
What changes by product type
Generic
155 working days · SAR 40,000- Bioequivalence study reports required, under the Gulf bioequivalence guidelines
- Where the comparator is not registered in the Kingdom, a full literature review of the active substance is required on top
- Triggers the 25% cut to the originator, and takes its own price ceiling
- SFDA publishes an approach to patents at the point of generic registration
Biologic and biosimilar
280 or 405 working days · SAR 95,000- A dedicated biosimilars guideline took effect in July 2026, covering biotechnology-derived proteins and polypeptides
- It excludes blood products, vaccines, advanced therapies and synthetic peptides
- Full dossier modules, with cell-bank characterisation, viral safety, comparability and process validation
- Triggers the 20% cut to the reference biological
A sourced negative worth having: the data requirements contain no requirement for local Saudi clinical studies and no requirement for a locally conducted bioequivalence study. Conducting trials in the Kingdom is governed separately and is a conduct standard, not a registration precondition.
What we could not confirm
- A fee schedule newer than 2011
The administrative decision SFDA still hosts dates from 2011. We found no successor, and no fee at all attached to the verification, abridged or priority pathways, or to variations.
- The priority review guidance
Version 5.3 is listed on SFDA's site but the file returns an error. Only the 168 working day figure from the framework is confirmed; the eligibility criteria are not.
- Which GMP authorities SFDA accepts
The rules say "the regulatory authorities in the country of origin" and name nobody. There is no published list and no statement that any certificate removes the inspection.
- When the MHRA joined the stringent list
Present in version 6.3, in force October 2020, and unchanged since. Earlier versions are not retrievable, so the first date is unknown — and SFDA has published nothing at all about Brexit.
SFDA states that only the Arabic text of its regulations and pricing rules is authentic. Everything quoted above is from SFDA's own published English translations, and where a point turns on exact wording we check the Arabic before it enters a client document.
If you also make devices, the answer is the opposite
Everything on this page is about medicines. For medical devices Saudi Arabia recognises nobody: the reliance route closed in 2020, there is one assessment for everyone, and a UKCA mark buys precisely nothing. Same regulator, same building, two different worlds — which is why a company selling both should not let one team's experience set the expectation for the other.
The medical devices page for Saudi Arabia → · What an MHRA approval is worth in all six markets →
Two weeks to a written route
Which pathway you qualify for, what the price will be after the reductions, whether your site needs an inspection, and where Saudi Arabia belongs in the order. In writing, with sources, for a fixed fee.
Or reach us directly — mail@bcabusiness.co.uk · +44 7342 901002 · WhatsApp
11 September 2026
Sources
- Regulatory Framework for Drugs Approval, DS-G-001 version 6.4, implementation 1 October 2023 — the stringent authority definition and every pathway timetable on this page. Note SFDA's own site still displays version 6.3 on the landing page while hosting 6.4 in its file library.
- Verification and Abridged Pathways, DS-G-020 version 3.0, implementation 20 January 2026 — the reference agencies, the two-year window and the sameness requirement. The same position appears in versions 2.1 and 2.2.
- Data Requirements for Human Drugs Submission, DS-REQ-002 version 4.0, updated August 2025 — the withdrawal of the certificate of pharmaceutical product, the bioequivalence requirements, and the contradictory "reference member state in EU" formulation.
- The Registration Rules of Pharmaceutical, Herbal and Health Product Manufacturers and their Products, DS-REQ-074 version 4.0, issued August 2022 — the agent requirement, manufacturer registration and SFDA's inspection right.
- Law of Pharmaceutical and Herbal Establishments and Products and its Implementing Regulations — the establishment licence, the scientific office and the five-year registration term with its SAR 1,000 statutory fee.
- Pricing Rules for Pharmaceutical Products, DS-REQ-082 version 3, board resolution effective 14 January 2021 — the sixteen-country basket including the United Kingdom, and every reduction on this page.
- General Guideline on Regulatory and Scientific Requirements for Biosimilars, DS-G-138 version 1.0, implementation 10 July 2026. GCC Guidelines for Bioequivalence, DS-G-010 version 3.1.
- Fees of Regulatory Services of Pharmaceutical Products, administrative decision 64/32 of 2011, unofficial English translation, still hosted by SFDA — all SAR figures in the fee column.
Re-checked quarterly and after any new version of the framework, the pathways guidance or the pricing rules. Two items sit on an active watch list: a successor fee schedule, and whether SFDA aligns its dossier guidance with the framework on the United Kingdom.